ArticleTranslational pediatrics2025
Transplanted oligodendrocyte progenitor cells improve neurological defects in a rat model of preterm white-matter injury during the sequela phase.
Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Preterm white-matter injury (PWMI), frequently occurring in preterm infants, is a major factor contributing to long-term neurological impairment and is a prevalent form of brain injury in this population. Therapies for this condition mainly target the acute phase, often leaving the chronic sequelae phase untreated. This study aimed to examine how transplanted human oligodendrocyte progenitor cells (hOPCs) differentiate and their therapeutic effectiveness in a rat model of PWMI sequelae. Methods: Hypoxia-ischemia was induced in neonatal rats at 3 days after birth and was followed by intracerebral transplantation of hOPCs (5×10 Results: Transplanted hOPCs remained viable in the brains of rats with PWMI sequelae for up to 13 weeks. They were found to be extensively dispersed in the damaged white matter and traversed along the corpus callosum toward the opposite hemisphere. About 83.34%±3.81% of the transplanted cells underwent differentiation to become oligodendrocyte lineage cells, among which about 77.15%±3.06% matured into oligodendrocytes that myelinated axons. IHC staining and TEM analyses showed that the myelin basic protein fluorescence intensity and myelin thickness were increased, pathological staining indicated that white-matter fiber injury was ameliorated, and the results of the Morris water maze test suggested that the cognitive function and neurobehavioral performance of the rats receiving transplanted hOPCs were restored. Conclusions: Transplanted hOPCs promoted remyelination, reduced white-matter injury, and improved neurobehavioral outcomes in PWMI rats during the sequela phase, suggesting that transplantation of hOPCs may be an effective therapeutic approach for children with neurological deficits associated with PWMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.